10-K: NextCure Faces Going Concern Amid ADC Pipeline Push

NextCure, Inc. reported continued net losses and a going concern warning for 2025, while advancing its lead antibody-drug conjugate candidates and securing additional financing.

Summary

• NextCure, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative antibody-drug conjugates (ADCs) for cancer patients.
• The company reported a net loss of $55.8 million for the year ended December 31, 2025, and an accumulated deficit of $436.0 million.
• Management has raised substantial doubt about the company's ability to continue as a going concern, with current cash, cash equivalents, and marketable securities of $41.8 million as of December 31, 2025, expected to fund operations only into the first half of 2027.
• SIM0505, a novel CDH6-targeted ADC, dosed its first U.S. patient in October 2025, with Phase 1 dose escalation data expected in Q2 2026.
• LNCB74, a B7-H4 targeted ADC, dosed its first patient in January 2025, and a protocol amendment in November 2025 allowed for higher dose escalation cohorts, with a trial update planned for H2 2026.
• The company underwent a restructuring in March 2024, pausing internal manufacturing operations and reducing its workforce by approximately 37%.
• NextCure secured $20.3 million in net proceeds from a private placement in November 2025 and entered into an at-the-market (ATM) offering agreement for up to $14.5 million in December 2025.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing with low sentiment due to the explicit "going concern" warning and continued significant net losses, despite some clinical progress and recent capital raises. The operational restructuring and deprioritization of programs highlight ongoing financial challenges.

Positives

• SIM0505, a CDH6-targeted ADC, advanced into U.S. Phase 1 clinical trials, with the first patient dosed in October 2025, and a data readout expected in Q2 2026.
• LNCB74, a B7-H4 targeted ADC, progressed in Phase 1 clinical trials, with the first patient dosed in January 2025, and a protocol amendment cleared in November 2025 to add higher dose escalation cohorts.
• Strategic focus on two differentiated ADC candidates (SIM0505 and LNCB74) targeting clinically validated oncology targets (CDH6 and B7-H4).
• Successful private placement in November 2025, raising $20.3 million in net proceeds, providing additional capital.
• Collaboration with Zaiming for SIM0505 is accelerating global development and regulatory timelines through a combined U.S.-China Phase 1 trial.
• Co-development agreement with LigaChem for LNCB74 involves equal sharing of development costs and future profits.

Negatives

• Substantial doubt exists about the ability to continue as a going concern, with current cash expected to fund operations only into the first half of 2027.
• Reported a net loss of $55.8 million for 2025 and an accumulated deficit of $436.0 million as of December 31, 2025.
• No products approved for commercial sale and no revenue generated from product sales to date.
• A restructuring in March 2024 involved pausing internal manufacturing operations and a 37% workforce reduction, indicating financial strain and a shift in operational strategy.
• Deprioritization of NC410 and NC525 clinical programs and non-oncology preclinical programs (NC605, NC181), with reliance on external partnering or financing for their advancement.
• Other income, net, decreased by $2.3 million to $1.8 million in 2025 due to lower investable cash and interest rates.

Risks

• Substantial additional financing will be required to pursue business objectives, which may not be available on acceptable terms, or at all, potentially forcing delays or termination of product development.
• The business is dependent on the ability to advance current and future product candidates through preclinical studies and clinical trials, marketing approval, and commercialization, each of which is uncertain.
• Regulatory approval processes are lengthy, expensive, and inherently unpredictable, and there is no guarantee of obtaining approval for any product candidate.
• Clinical development involves a lengthy and expensive process with uncertain outcomes, and the organization has limited experience designing and implementing pivotal clinical trials.
• Current or future product candidates may cause undesirable side effects or have other properties that could halt clinical development, delay or prevent regulatory approval, or limit commercial potential.
• Difficulties in enrolling patients in clinical trials could delay or adversely affect clinical development activities.
• The approach to the discovery and development of product candidates using the FIND platform is unproven and may not result in marketable products.
• Manufacturing experience is limited, particularly following the recent restructuring that paused manufacturing operations, and there is dependence on third-party suppliers and contract manufacturing organizations (CMOs).
• The loss of third-party manufacturing partners or their failure to comply with regulatory requirements or supply sufficient quantities could materially and adversely affect the business, including potential impacts from the BIOSECURE Act on Chinese CMOs like WuXi XDC.
• Obtaining and maintaining robust patent protection for product candidates is uncertain, and competitors could develop and commercialize similar products.
• Reliance on third parties to conduct preclinical studies and clinical trials poses risks if they do not successfully carry out contractual duties or meet deadlines.
• Dependence on third-party collaborators for discovery, development, and commercialization of product candidates (e.g., LigaChem) carries risks if collaborations are not successful or are terminated.
• High dependence on key personnel, and failure to attract, motivate, and retain highly qualified personnel could impede business strategy.
• Significant competition from other biotechnology and pharmaceutical companies could adversely affect operating results.
• Product liability lawsuits against the company could cause substantial liabilities and limit commercialization of product candidates.
• The ability to use net operating loss carryforwards to offset future taxable income may be subject to limitations due to ownership changes.
• Natural disasters or other unexpected events may disrupt operations, adversely affect results, and may not be covered by insurance.
• Anti-takeover provisions in charter documents and Delaware law could make an acquisition more difficult and may prevent attempts by stockholders to replace or remove current management.
• The company may be subject to claims asserting that employees, consultants, or advisors have wrongfully used or disclosed alleged trade secrets of their current or former employers, including a lawsuit filed in 2021 against the company and its CEO.

Future Outlook

NextCure expects to continue incurring significant expenses and operating losses for the foreseeable future, with profitability not anticipated for several years, if ever. Current cash, cash equivalents, and marketable securities are projected to fund operations into the first half of 2027, necessitating substantial additional funding. The company plans to provide Phase 1 dose escalation data for SIM0505 in Q2 2026 and a trial update for LNCB74 in H2 2026. It also seeks partners or third-party financing for its other clinical and preclinical programs, with potential IND filings for non-oncology programs within 12 to 18 months if funded.

Management Comments

• "We are uniquely positioned in the ADC field, with ADCs targeting two clinically validated targets, leveraging two distinct payloads: a Topoisomerase 1 inhibitor (SIM0505 targeting CDH6) and a Tubulin Inhibitor (LNCB74 targeting B7-H4)."
• "By conducting a combined U.S.-China Phase 1 trial in partnership with Zaiming, we have cost-effectively accelerated our global development and regulatory timelines."
• "Building on our strong know-how and previous clinical experience with B7-H4, we have created a new mAb intermediate and combined it with LigaChem's differentiated ADC technology to create a promising B7-H4 ADC for the treatment of B7-H4 expressing cancers."
• "Given the multi-line nature of ovarian cancer treatment, patients require sequential ADC therapies targeting distinct antigens. By offering both TOPOi and Tubulin payloads, we address mechanisms of resistance and maximize tumor eradication, providing a distinct competitive advantage in treatment durability."
• "We believe that both of these non-oncology programs [NC181 and NC605] have the potential to file an IND application within 12 to 18 months if financial support from partners or third parties is secured."
• "Our expectation to incur additional operating losses and negative operating cash flows in the future and the need for additional funding to support our planned operations raise substantial doubt regarding our ability to continue as a going concern for a period of one year after the date that these audited financial statements are issued."

Industry Context

StockSavvy.ai notes that NextCure's strategic focus on antibody-drug conjugates (ADCs) aligns with a growing trend in oncology, where ADCs are gaining traction as a targeted therapy approach. The company's dual-payload strategy (Topoisomerase 1 inhibitor for SIM0505 and Tubulin Inhibitor for LNCB74) aims to address mechanisms of resistance, a critical challenge in cancer treatment, particularly in multi-line therapies like ovarian cancer. The competitive landscape for CDH6-targeted programs includes established players like Merck & Co. and Daiichi Sankyo (with raludotatug deruxtecan), and for B7-H4, companies such as AstraZeneca, BeiGene, and GSK are also in clinical trials, indicating a highly competitive but potentially lucrative market. The company's reliance on collaborations (Zaiming, LigaChem) is a common strategy for smaller biotechs to share development costs and leverage external expertise, especially given the high capital requirements and risks in drug development.

Comparison to Industry Standards

• NextCure's SIM0505 (Phase 1) faces competition from more advanced CDH6 candidates like raludotatug deruxtecan (Phase 2/3), co-developed by Merck & Co. and Daiichi Sankyo, as well as other early-stage programs such as OnCusp Therapeutics' CUSP06 and Hansoh Pharma's HS-20124.
• In ovarian cancer, SIM0505 may also compete with alternative targeted modalities, including Folate Receptor Alpha (FR) therapies like AbbVie's commercially marketed Elahere and Genmab's clinical candidate rinatabart sesutecan (Rina-S), and TUB-040 (targeting NaPi2b).
• LNCB74 competes with other B7-H4 targeted programs in clinical trials from companies including AstraZeneca plc, BeiGene Ltd. (licensed from DualityBio), GSK plc (licensed from Hansoh Pharmaceutical Group Limited), and Day One Biopharmaceuticals, Inc. (acquired Mersana Therapeutics).
• The company's accumulated deficit of $436.0 million and ongoing net losses are typical for clinical-stage biopharmaceutical companies, but the explicit 'going concern' warning indicates a more immediate and severe financial challenge compared to many industry peers who might have longer cash runways.
• The 1:12 reverse stock split in July 2025 is often a measure taken by companies to maintain listing requirements or improve stock perception, which can be viewed negatively by investors compared to companies with sustained higher stock prices.

Management Changes

Corporate Governance

Legal Proceedings

• A lawsuit was filed in Federal court in 2021 by a third party against the company, with claims added in 2022 to include the Chief Executive Officer as a co-defendant, alleging breach of contractual and fiduciary duties and improper utilization of the plaintiff's confidential information related to discovery efforts.

Related Party Transactions

• On June 13, 2025, the company entered into a License Agreement with Simcere Zaiming Pharmaceutical Co., Ltd. (Zaiming), a biopharmaceutical company based in China.
• In connection with the License Agreement, the company also entered into a Subscription Agreement with Simcere Zaiming, Inc., an affiliate of Zaiming, for a private placement of 338,636 shares of common stock for $2.0 million.
• The company has a Research Collaboration and Co-Development Agreement with LigaChem Biosciences, Inc. (LigaChem) since November 2022, where both parties equally share costs and profits for co-development products like LNCB74.

Stakeholder Impact

• Shareholders face potential dilution from recent and future equity offerings, stock price volatility, and the risk of losing investment due to the 'going concern' warning. Anti-takeover provisions limit their influence on corporate matters.
• Employees experienced a workforce reduction of approximately 37% in March 2024 due to restructuring, and the company's success depends on attracting and retaining highly qualified personnel.
• Future patients may benefit from the development of new cancer treatments (SIM0505, LNCB74) if they receive regulatory approval, but clinical trial failures or delays pose risks.
• Creditors face increased risk due to the 'going concern' warning and the company's ongoing need for additional financing.
• Partners (Zaiming, LigaChem) are engaged in ongoing collaboration and co-development efforts, sharing costs and potential profits, with Zaiming also becoming a shareholder.

Next Steps

• Provide Phase 1 dose escalation data readout for SIM0505 in Q2 2026.
• Initiate Dose Expansion and Optimization phase for SIM0505 in Q2 2026.
• Provide a trial update for LNCB74 in H2 2026.
• Seek partnering, licensing, or other strategic approaches for NC410 and NC525 clinical oncology programs.
• Pursue a partner or third-party financing to advance preclinical non-oncology programs NC605 and NC181, with potential IND filings within 12 to 18 months if funded.
• Raise additional capital by partnering, selling equity, or other means to fund operations beyond H1 2027.

Key Dates

Recommendation

The explicit "substantial doubt about our ability to continue as a going concern" is a critical red flag for investors. Despite some clinical progress and recent capital raises, the company's significant accumulated deficit, ongoing net losses, and short cash runway (into H1 2027) indicate severe financial instability. The restructuring and workforce reduction further underscore these challenges. The highly competitive ADC market, coupled with the early stage of NextCure's lead candidates, means a long and uncertain path to profitability. Investors face high risk of further dilution and potential loss of capital.

Keywords

Biopharmaceutical, Oncology, Antibody-Drug Conjugates, Clinical-stage, SIM0505, LNCB74, CDH6, B7-H4, Phase 1 clinical trials, Cancer treatment, Drug development, Biotech, Going concern, Private placement, Restructuring, Intellectual property, Regulatory approval, Nasdaq